Score Overview
BioCryst Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 17M to $ 874M and net income went from -$ 182M to $ 263M. Revenue increased in every one of those 5 years; net income in 3.
Across BioCryst Pharmaceuticals Inc's full reported history, from 1994 to 2025, revenue grew from $ 700K to $ 874M and net income went from -$ 6M to $ 263M. Revenue increased in 50% of the years measured; net income in 41%.
BioCryst Pharmaceuticals Inc currently holds a 20-year HDB Score of 3.0 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 10.59 | — |
1 Year2025-08-12 | $ 8.35 | 26.83% |
5 Years2021-08-12 | $ 16.64 | -36.36% |
10 Years2016-08-12 | $ 5.04 | 110.12% |
20 Years2006-08-11 | $ 8.91 | 18.86% |
30 Years1996-08-12 | $ 14.00 | -24.36% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | 30 Years1996-08-12 |
|---|---|---|---|---|---|---|
| Price | $ 10.59 | $ 8.35 | $ 16.64 | $ 5.04 | $ 8.91 | $ 14.00 |
| Return | — | 26.83% | -36.36% | 110.12% | 18.86% | -24.36% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 940M | -$ 384M | $ 352M |
| 2025 | $ 874M | $ 263M | $ 274M |
| 2024 | $ 450M | -$ 88M | $ 321M |
| 2023 | $ 331M | -$ 226M | $ 388M |
| 2022 | $ 270M | -$ 247M | $ 424M |
| 2021 | $ 157M | -$ 184M | $ 507M |
| 2020 | $ 17M | -$ 182M | $ 300M |
| 2019 | $ 48M | -$ 108M | $ 136M |
| 2018 | $ 20M | -$ 101M | $ 126M |
| 2017 | $ 25M | -$ 65M | $ 155M |
| 2016 | $ 26M | -$ 55M | $ 63M |
| 2015 | $ 48M | -$ 43M | $ 99M |
| 2014 | $ 13M | -$ 45M | $ 113M |
| 2013 | $ 17M | -$ 30M | $ 40M |
| 2012 | $ 26M | -$ 39M | $ 36M |
| 2011 | $ 19M | -$ 56M | $ 41M |
| 2010 | $ 63M | -$ 32M | $ 53M |
| 2009 | $ 74M | -$ 13M | $ 68M |
| 2008 | $ 56M | -$ 24M | $ 61M |
| 2007 | $ 71M | -$ 29M | $ 50M |
| 2006 | $ 6M | -$ 43M | $ 37M |
| 2005 | $ 151.87K | -$ 26M | $ 50M |
| 2004 | $ 336.9K | -$ 21M | $ 23M |
| 2003 | $ 1M | -$ 12M | $ 20M |
| 2002 | $ 1M | -$ 16M | $ 24M |
| 2001 | $ 11M | -$ 4M | $ 31M |
| 2000 | $ 3M | -$ 11M | $ 24M |
| 1999 | $ 2M | -$ 5M | $ 23M |
| 1998 | $ 6M | -$ 4M | $ 12M |
| 1997 | $ 1M | -$ 10M | $ 3M |
| 1996 | $ 2M | -$ 7M | $ 3M |
| 1995 | $ 200K | -$ 8M | $ 6M |
| IPO1994 | $ 700K | -$ 6M | $ 2M |
Explore beyond BCRX
You're looking at BioCryst Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
